Michael Wolf
Impact in
Papers in
-
- Statistical Methods and Inference 31
- Statistical Methods in Clinical Trials 27
- Statistical Methods and Bayesian Inference 22
- Advanced Statistical Methods and Models 15
- Finance 38
- Financial Risk and Volatility Modeling 30
- Financial Markets and Investment Strategies 17
- Co-authors
- Olivier Ledoit (34 shared papers)Joseph P. Romano (39 shared papers)Salvatore Siena (10 shared papers)Marc Peeters (9 shared papers)Eric Van Cutsem (8 shared papers)Rafael G. Amado (5 shared papers)Roy S. Herbst (11 shared papers)Steven D. Averbuch (6 shared papers)
- Journals
- Journal of Clinical Oncology (13 papers)The Annals of Statistics (6 papers)Investigational New Drugs (5 papers)Lung Cancer (4 papers)Journal of Time Series Analysis (3 papers)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Michael Wolf
183 papers receiving 19.3k citations
Michael Wolf's Hit Papers
Peers
Comparison fields: 5 of 196
- Finance 3.5k
- Oncology 7.6k
- Statistics and Probability 2.1k
- Pulmonary and Respiratory Medicine 5.4k
- Management Science and Operations Research 1.7k
Countries citing papers authored by Michael Wolf
This map shows the geographic impact of Michael Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wolf more than expected).
Fields of papers citing papers by Michael Wolf
This network shows the impact of papers produced by Michael Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wolf. The network helps show where Michael Wolf may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Wolf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 188 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 2406 |
| 2 | Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Hit paper breakdown → | 2003 | 2121 |
| 3 | A well-conditioned estimator for large-dimensional covariance matrices Hit paper breakdown → | 2003 | 1751 |
| 4 | Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2007 | 1520 |
| 5 | Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 Hit paper breakdown → | 2004 | 1388 |
| 6 | Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 Hit paper breakdown → | 2004 | 1373 |
| 7 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1355 |
| 8 | Improved estimation of the covariance matrix of stock returns with an application to portfolio selection Hit paper breakdown → | 2003 | 1044 |
| 9 | Robust performance hypothesis testing with the Sharpe ratio Hit paper breakdown → | 2008 | 633 |
| 10 | Subsampling Hit paper breakdown → | 1999 | 519 |
| 11 | 2012 | 267 | |
| 12 | 2016 | 217 | |
| 13 | 2008 | 199 | |
| 14 | 2017 | 182 | |
| 15 | 2003 | 179 | |
| 16 | 2005 | 163 | |
| 17 | 2002 | 163 | |
| 18 | The Romano–Wolf multiple-hypothesis correction in Stata Hit paper breakdown → | 2020 | 157 |
| 19 | 2017 | 157 | |
| 20 | The financial burden of cancer: estimates from a study of insured women with breast cancer. | 2004 | 152 |
About Michael Wolf
Michael Wolf is a scholar working on Statistics and Probability, Finance, Oncology, Management Science and Operations Research and Pulmonary and Respiratory Medicine, having authored 188 papers that have together received 20.0k indexed citations. Recurring topics across this work include Statistical Methods and Inference (31 papers), Financial Risk and Volatility Modeling (30 papers), Statistical Methods in Clinical Trials (27 papers), Statistical Methods and Bayesian Inference (22 papers), Financial Markets and Investment Strategies (17 papers), Colorectal Cancer Treatments and Studies (16 papers), Lung Cancer Treatments and Mutations (16 papers) and Advanced Statistical Methods and Models (15 papers). The work is most often cited by research in Finance (3.5k citations), Oncology (7.6k citations), Statistics and Probability (2.1k citations), Pulmonary and Respiratory Medicine (5.4k citations) and Management Science and Operations Research (1.7k citations). Michael Wolf has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Olivier Ledoit, Joseph P. Romano, Salvatore Siena, Marc Peeters, Eric Van Cutsem, Rafael G. Amado, Roy S. Herbst, Steven D. Averbuch, Joan H. Schiller and Ronald B. Natale. Their work appears in journals such as Journal of Clinical Oncology, The Annals of Statistics, Investigational New Drugs, Lung Cancer and Journal of Time Series Analysis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.